In this study, we profiled plasma from individuals with ALS, asymptomatic C9 repeat expansion carriers (AsymC9), and healthy controls, to determine whether this novel, ultra‐sensitive immunoassay will both detect known ALS plasma biomarkers, as well as reveal new targets of interest. The gene discussed is C9; the disease is amyotrophic lateral sclerosis.